Partial reversibility of cisplatin nephrotoxicity in children
- PMID: 2007926
- DOI: 10.1016/s0022-3476(05)83372-4
Partial reversibility of cisplatin nephrotoxicity in children
Abstract
To evaluate the long-term renal toxicity of cisplatin, 40 children who had been without treatment at least 18 months (range 18 months to 7 years) were observed. In all the children, glomerular filtration rate (GFR) was estimated from the plasma clearance of chromium 51-labeled ethylenediaminetetraacetic acid, both at the end of treatment and at a median follow-up of 2 years 6 months after treatment was stopped (range 18 months to 7 years). In 21 children, serum magnesium level was also measured at follow-up. Median age at diagnosis was 15 months (range 13 days to 13 years 8 months), and median cumulative doses of cisplatin was 500 mg/m2 (range 120 to 1860 mg/m2). In 22 of 24 children with an end-of-treatment GFR of less than 80 ml/min per 1.73 m2, the median improvement in GFR at follow-up was 22 ml/min per 1.73 m2 (range 2 to 56 ml/min per 1.73 m2). Hypomagnesemia was found in 6 of 21 children and was independent of GFR. No significant correlation was found between improvement in renal function and total cisplatin dose, age, gender, tumor type, or associated nephrotoxic medication. We conclude that most children have some recovery from cisplatin glomerular toxicity, especially if damage is not severe, but that hypomagnesemia may persist.
Similar articles
-
Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors.Eur J Cancer. 2009 Dec;45(18):3213-9. doi: 10.1016/j.ejca.2009.06.032. Epub 2009 Oct 21. Eur J Cancer. 2009. PMID: 19850470
-
Cisplatin dose rate as a risk factor for nephrotoxicity in children.Br J Cancer. 1998 May;77(10):1677-82. doi: 10.1038/bjc.1998.276. Br J Cancer. 1998. PMID: 9635848 Free PMC article.
-
Renal toxicity of cancer chemotherapeutic agents in children: ifosfamide and cisplatin.Curr Opin Pediatr. 1995 Apr;7(2):208-13. doi: 10.1097/00008480-199504000-00016. Curr Opin Pediatr. 1995. PMID: 7787938 Review.
-
The long-term effect of cisplatin on renal function.Cancer. 1986 Nov 15;58(10):2214-7. doi: 10.1002/1097-0142(19861115)58:10<2214::aid-cncr2820581009>3.0.co;2-i. Cancer. 1986. PMID: 3756770
-
Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer.Cochrane Database Syst Rev. 2013 Oct 8;(10):CD008944. doi: 10.1002/14651858.CD008944.pub2. Cochrane Database Syst Rev. 2013. Update in: Cochrane Database Syst Rev. 2019 Mar 11;3:CD008944. doi: 10.1002/14651858.CD008944.pub3 PMID: 24101439 Updated. Review.
Cited by
-
Pattern and impact of drugs targeted toward toxicity amelioration in patients receiving cancer chemotherapy.Perspect Clin Res. 2018 Jan-Mar;9(1):23-30. doi: 10.4103/picr.PICR_156_16. Perspect Clin Res. 2018. PMID: 29430414 Free PMC article.
-
Cisplatinum nephrotoxicity in oncology therapeutics: retrospective review of patients treated between 2005 and 2012.Pediatr Nephrol. 2014 Dec;29(12):2421-4. doi: 10.1007/s00467-014-2935-z. Epub 2014 Aug 30. Pediatr Nephrol. 2014. PMID: 25171948
-
Pediatric Onco-Nephrology: Time to Spread the Word-Part II: Long-Term Kidney Outcomes in Survivors of Childhood Malignancy and Malignancy after Kidney Transplant.Pediatr Nephrol. 2022 Jun;37(6):1285-1300. doi: 10.1007/s00467-021-05172-y. Epub 2021 Sep 6. Pediatr Nephrol. 2022. PMID: 34490519
-
Acute kidney injury in a child treated with cisplatin and amphotericin B.Cancer Chemother Pharmacol. 2024 Oct;94(4):623-626. doi: 10.1007/s00280-024-04705-0. Epub 2024 Aug 7. Cancer Chemother Pharmacol. 2024. PMID: 39110201 Free PMC article.
-
Renal function following unilateral nephrectomy for neuroblastoma and Wilms' tumour.Pediatr Nephrol. 1995 Oct;9(5):579-82. doi: 10.1007/BF00860940. Pediatr Nephrol. 1995. PMID: 8580014
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
